ZHZhe Huang

Zhe Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhe Huang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiers

    by Yanmei Rao, Li Dong, Zhe Huang

    Advanced therapeutic medicinal products represent a broad spectrum of biopharmaceutical innovations that prominently feature cell and gene therapy formulations. These cutting-edge therapeutic modalities are specifically engineered to intervene in and prevent illnesses that historically necessitated continuous, long-term management. To visually portray the most recent trajectories in cell and gene therapy investigations and to map out prevailing global advancements, a bibliometric assessment was conducted. This analysis meticulously sourced its data from the Web of Science Core Collection database and was significantly enhanced by analytical platforms such as VOSviewer and CiteSpace. Cell and gene therapy products demonstrate considerable promise for both foundational scientific inquiry and diverse clinical interventions, with their utility now extending far beyond cancer treatment to encompass a wide array of other pathological conditions. This paper provides a comprehensive examination of the evolving trends, collaborative endeavors, and burgeoning frontiers within the dynamic landscape of cell and gene therapy products. Graphical abstract

  • Open Access

    Cost-effectiveness analysis of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer

    by Xiaofeng Lin, Yipeng Lan, Jing Wang, Wei Zhao, Xiaoxi Liu, Zhe Huang

    The MONARCH 3 trial has demonstrated that Anastrozole combined with Abemaciclib is safe and effective for the treatment of postmenopausal hormone receptor-positive advanced breast cancer. However, its cost-effectiveness for long-term use has not been investigated yet. This study aims to evaluate the cost-effectiveness of Anastrozole combined with Abemaciclib versus Anastrozole used alone for patients in China. Based on MONARCH 3 trial data, we constructed a Markov model using Treeage Pro 2022 software. The model cycle was set at 1 month over a period of 20- year time horizon, and the annual discount rate was set at 5%. The cost-utility analysis was used to assess the cost-effectiveness of Anastrozole combined with Abemaciclib for the treatment of postmenopausal hormone receptor-positive advanced breast cancer. The output indexes of the model were cost and quality-adjusted life year (QALY), and the model evaluation index was incremental cost-effectiveness ratio (ICER). The willingness to pay (WTP) threshold was set at 3 times the per-capita gross domestic product (GDP) of China in 2023 (¥268,074/QALY). Meanwhile, one-way sensitivity analysis and probabilistic sensitivity analysis were used to explore the uncertainties of the model and parameters. Anastrozole combined with Abemaciclib provided more health benefits than Anastrozole used alone, however, the total cost was higher. The incremental utility and incremental cost were 0.01 QALYs and ¥1075.51, respectively. And the ICER of the two regimens was ¥93,940.83/QALY, which was less than 3 times the per-capita GDP of China in 2023 (¥268,074). The results of the sensitivity analysis attested that the study results were robust. Anastrozole combined with Abemaciclib is more cost-effective than Anastrozole used alone for the treatment of postmenopausal hormone receptor-positive advanced breast cancer.

  • Open Access

    Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Chronic spontaneous urticaria (CSU) is a common inflammatory immune skin disease. It has a serious impact on the patients’ quality of life and imposes a serious financial burden on patients. The standard therapy for CSU (using antihistamines), while less costly, has limited efficacy and no longer adequately meets the clinical needs of CSU patients. Omalizumab is the world’s first and currently the only biologic approved for the treatment of CSU. Several studies have confirmed the efficacy and safety of omalizumab for CSU. However, the economics of omalizumab treatment relative to standard therapies remains unknown in China. The purpose of this study was to analyze the cost-effectiveness of omalizumab versus standard treatments for CSU after omalizumab’s inclusion in the National Drug Insurance List from the patient’s perspective. We developed a Markov model based on the Urticaria Activity Score over 7 days (UAS7). The modeling period was 4 weeks. The time horizon was 10 years. The willingness-to-pay threshold (WTP) of 1–3 times gross domestic product (GDP) per capita was selected. Incremental cost-effectiveness ratio (ICER) was calculated from the base-case analysis, and one-way sensitivity analysis and probabilistic sensitivity analysis were performed. The ICER of omalizumab treatment relative to standard treatment was ¥160,411/QALY, which was between 1 and 3 times GDP per capita. Sensitivity analyses illustrated that the direct cost of omalizumab had a significant effect on the ICER and demonstrated the stability of the results. Omalizumab treatment is a cost-effective regimen compared with standard therapy under certain circumstances. This demonstrates the important role that health insurance policies play in reducing the burden on CSU patients. However, the limitations of applying foreign clinical data in this paper and the uncertainty of cost-effectiveness at a low WTP threshold are two aspects that cannot be ignored, and subsequent related studies are needed. This study will help patients to make decisions about treatment options, and will be a reference to relevant healthcare organizations.


  • Open Access

    Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Background: Gaucher disease (GD) is an autosomal recessive disorder with a wide range of clinical symptoms that cause abnormal function of parenchymal organs such as liver and spleen in patients. Enzyme replacement therapy, represented by imiglucerase, is a common approach for GD treatment. However, limited efficacy and high cost are important factors restricting its use. Ambroxol has gradually attracted attention due to its ease of administration, safety, and efficacy. However, there is no pharmacoeconomic evaluation of ambroxol for the treatment of GD in China. The cost-effectiveness profile of ambroxol combined with imiglucerase therapy for the treatment of GD, as opposed to imiglucerase monotherapy, needs to be investigated.Objective: This study aimed to analyze the cost-effectiveness of ambroxol for GD in China from the perspective of the Chinese healthcare system.Methods: We constructed an eight-state Markov model based on the disease characteristics of GD. The Markov cycle was 1 month. The time horizon was 6 years. The willingness-to-pay threshold was chosen to be 1–3 times the gross national product (GDP) per capita. The incremental cost-effectiveness ratio (ICER) was calculated from the base-case analysis, and one-way sensitivity analyses and probabilistic sensitivity analyses were performed.Results: The ICER value was ¥223,726.70, which was between 1 and 3 times GDP per capita. Sensitivity analysis showed that the cost of imiglucerase had a significant effect on ICER as well as demonstrating the stability of the results.Conclusion: Ambroxol combination therapy is a cost-effective regimen compared with imiglucerase monotherapy.


  • Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    As a rare disease with the largest number of cases in China, spinal muscular atrophy (SMA) causes severe motor deficits as well as multi-system organ damage. Some potent drugs for SMA, such as Nusinersen (NU) and Risdiplam (RI) represented by targeted survival motor neuron gene therapy, have become a new trend in the treatment of SMA. RI has gradually attracted attention due to its ease of administration, safety, and efficacy. The study was to analyze the cost-effectiveness of RI and NU for the treatment of SMA in China from the perspective of the healthcare system. We constructed a five-state Markov model based on the different stages of SMA. The willingness-to-pay threshold was chosen to be 1-3 times the gross domestic product (GDP) per capita. The base-case analysis was used to calculate the incremental cost-effectiveness ratio (ICER), and one-way and probabilistic sensitivity analyses were performed. The ICER value was ¥132,402.10/QALY, which was in the range of 1-3 times GDP per capita. Sensitivity analysis results showed the cost of RI and NU had a significant effect on ICER as well as proving the stability of results. RI is a cost-effective option compared to NU in SMA treatment.


  • Open Access

    Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system

    by Xiaochen Peng, Haiyin Wang, Hui Sun, Xiaoxiao Qin, Zhe Huang

    Background: An increasing number of countries worldwide, including China, have adopted Health Technology Assessment (HTA) and pharmacoeconomic (PE) principles, either comprehensively or partially, to inform drug reimbursement decisions. While China has integrated the annual cost of the drug (ACD) as a key economic factor considered in decision-making, implicitly establishing a price ceiling for medical insurance coverage. However, the current approach lacks a robust theoretical foundation and quantitative evidence.Objective: This study aims to explore the rationale for incorporating ACD as a constraint in reimbursement decision-making framework, and to estimate a practical ACD threshold for China’s basic medical insurance (BMI) system.Methods: Binary logistic regression was employed to analyze the impact of ACD on patients’ financial burden. The outcome variable was the occurrence of financial barriers, with ACD serving as the primary independent variable. Covariates are factors of reimbursement benefits, including reimbursement caps and reimbursement rates. Average marginal effect analysis was performed to quantify the relationship between ACD and the likelihood of encountering barriers, suggesting a ACD threshold with practical implications for reimbursement decisions. Multicollinearity among variables was assessed using the Variance Inflation Factor (VIF). The model’s goodness of fit was assessed using the likelihood-ratio test and the Hosmer-Lemeshow test. Additionally, model performance was evaluated using the Receiver Operating Characteristic (ROC) curve.Findings: In China, patients face significant challenges in affording high-priced medications under BMI system. Failure to consider the payment capacity of the general population in drug reimbursement decision-making can result in an inequitable allocation of basic medical insurance funds. Logistic regression analysis revealed that for each 10,000 CNY (approximately 1,431 USD) increase in the ACD, the odds of outcome occurring increased by a factor of 1.1681 (95% CI: 1.1365–1.2006, p < 0.001). The highest average marginal effect was observed at a ACD value of 400,000 CNY (0.0228; 95% CI: 0.0199–0.0256, p < 0.0001). Furthermore, when ACD exceeded 440,000–450,000 CNY, the predicted probability of financial barriers surpassed 50% (p < 0.001).Conclusion: Incorporating the evaluation of ACD into the appraisal process is crucial for informing reimbursement decisions, especially in health insurance systems without robust safety net mechanisms for patients. This study innovatively estimated the value of ACD threshold, addressing the research gap and providing a methodological reference for quantitative research. Despite adopting maximized reimbursement benefits of BMI, the estimated ACD threshold appears unable to support innovative medications priced comparably to those in global markets. In the future, China should establish a risk-sharing mechanism and improve the level of medical reimbursement benefits to mitigate financial barriers for patients’ access to high-value medications.


  • Open Access

    Cost-effectiveness analysis of enzyme replacement therapy for the treatment of Chinese patients with fabry disease: a Markov model

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Background: Fabry disease (FD) is an X-chromosome-linked genetic disorder. Currently, the main treatments for FD include disease-nonspecific and disease-specific treatments. Nonspecific treatment involves symptomatic management of organ involvement. On the other hand, disease-specific treatment is to regulate the activity of the corresponding enzymes, which is targeted. Among them, enzyme replacement therapy (ERT) is a classical therapy. Several studies have demonstrated the significant ameliorative effect of agalactosidase-α (ALTA-a) on cardiac and renal function in patients with FD. Despite the excellent clinical performance, there are limited pharmacoeconomic studies on ERT for FD worldwide.Objective: The aim of this study was to analyze the cost-effectiveness of ERT for FD in China from the perspective of the healthcare system.Methods: We constructed a five-state Markov model based on the disease characteristics of FD. The modeling period was 1 month. The time horizon was 3 years. The willingness-to-pay threshold was chosen as 1-3 times the gross national product (GDP) per capita. The incremental cost-effectiveness ratio (ICER) was calculated from the base case analysis, and one-way sensitivity analysis and probabilistic sensitivity analysis were performed.Results: The ICER value is ¥148071.95/QALY, which is between 1-3 times GDP per capita. The sensitivity analysis showed that the cost of ALTA-a had a significant effect on ICER and proved the stability of the results.Conclusion: ERT therapy is a cost-effective program compared to “No ERT” therapy.


  • Open Access

    Research on technological innovation decision-making considering government subsidies and corporate reputation

    by Yu Kang, Zhe Huang

    Aiming at the information asymmetry between pharmaceutical enterprises’ technological innovation decisions and government subsidy strategy, this paper establishes a differential game model consisting of the government and a single pharmaceutical company, proposes three different government subsidy strategies, and obtains an equilibrium solution with the help of the Hamilton-Jacobi-Bellman equation, taking into consideration of the transmission effect of the enterprise’s reputation. First, the innovation decisions of pharmaceutical firms without government subsidies are analysed, and based on this, the optimal strategies with government subsidies for non-cooperative pacts and cooperation between the government and enterprises are analysed separately. In addition, the effects of different subsidy strategies on the government’s investment efficiency, corporate reputation, and the choice of corporate innovation strategies are compared, and the results are verified by numerical analysis. Finally, based on the results of the study, references and suggestions are provided for the formulation of government subsidy policies as well as corporate innovation decisions. The results show that: government subsidies can effectively stimulate the innovation ability of pharmaceutical enterprises and improve their reputation; the more sensitive an enterprise’s reputation is to the coefficient of technological innovation, the more it can improve the enterprise’s innovation level; and the coordination contract of government-enterprise cooperation can realize the Pareto improvement of the benefits of the government and enterprises.